What's in Alzahraa Ahmed Abbas's pipeline?

Alzahraa Ahmed Abbas has 1 drugs in our index: 1 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Alzahraa Ahmed Abbas's portfolio?

No competitive overlap detected.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/alzahraa-ahmed-abbas.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

Alzahraa Ahmed Abbas — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Alzahraa Ahmed Abbas pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Bupivacaine + nalbuphine	Bupivacaine + nalbuphine	marketed	Local anesthetic + mixed opioid agonist-antagonist	Voltage-gated sodium channels (bupivacaine); kappa and mu opioid receptors (nalbuphine)	Pain management, Anesthesia

Therapeutic area mix

Pain management, Anesthesia · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

No competitive overlap data.

Subscribe to ongoing alerts

Every new pipeline event for Alzahraa Ahmed Abbas:

Cite this brief

Drug Landscape (2026). Alzahraa Ahmed Abbas — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/alzahraa-ahmed-abbas. Accessed 2026-05-17.